ClinicalTrials.gg
Not yet recruitingNCT07559513OPTIMA-2Updated Nov 12, 2026

A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 3 interventional study of garetosmab in Fibrodysplasia Ossificans Progressiva and FOP, sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Oct 8, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years.

The aim of the study is to see how safe, tolerable, and effective the study drug is.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
02

Conditions studied

  • Fibrodysplasia Ossificans Progressiva
  • FOP

Keywords

  • ACVR1
  • ACVR1 Mutation
  • Activin A Receptor Type 1
  • ALK2 Mutation
  • Fibrodysplasia Ossificans Congenita
  • FOP-causing Mutation
  • Heterotopic Ossification
  • Münchmeyer Disease
  • Myositis Ossificans Progressiva
  • Progressive Heterotopic Ossification
  • Progressive Myositis Ossificans
  • Skeletal Dysplasia
  • Stone Man Disease
03

In context

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

This study's planned enrollment of 18 is below the median of 48 across 16 interventional studies indexed under Myositis Ossificans.

Browse Myositis Ossificans studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. For USA participants, age criteria are 4 to \< 18 years old, at the time of the administration of the first dose of study intervention. Non-USA participants age criteria are 2 to \< 18 years old
  2. Must have a confirmation of FOP diagnosis, as described in the protocol
  3. At the time of enrollment, participants must weight:

    1. Cohort 1: more than 30 kg (or 66.1 pounds)
    2. Cohort 2: more than 30 kg (or 66.1 pounds)
    3. Cohort 3: less than or equal to 30 kg (or 66.1 pounds)

Key Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS) score > 19 at the time of screening
  2. Participant has significant concomitant illness or history of significant illness, as described in the protocol
  3. Previous history or diagnosis of cancer
  4. Ongoing significant viral or bacterial illness, within 2 weeks of the first study drug administration
  5. History of severe respiratory compromise requiring oxygen, respiratory support
  6. Known history of cerebral vascular malformation
  7. Participants with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
  8. Participants with a known pre-existing medical history of a bleeding diathesis, as described in the protocol
  9. Participants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Adolescents

    Participants aged 12 - 18 years old

    Drug: garetosmab

  • Experimental
    Cohort 2: Children

    Children who are 4 to 12 years old (for non-US sites only 2 to 12 years old)

    Drug: garetosmab

  • Experimental
    Cohort 3: Children and Adolescents

    Participants and Children aged 4 to 18 years old (for non-US sites only 2 to 18 years old)

    Drug: garetosmab

Interventions

  • Administered per the protocol

    Also known as: REGN2477, PASATRU™

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-Emergent Adverse Event (TEAEs)

    Time frame: Baseline to week 56

  2. Severity of TEAEs

    Time frame: Baseline to week 56

  3. Concentrations of functional garetosmab in serum

    Time frame: Through week 56

Secondary outcomes

  1. Total volume of new Heterotopic Ossification (HO) lesions

    Time frame: At week 28 and week 56

  2. Number of new HO lesions

    Time frame: At week 28 and week 56

  3. Occurrence of new HO lesions

    Time frame: At week 28 and week 56

  4. Number of clinician-assessed flare-ups

    Time frame: Through week 28 and week 56

  5. Occurrence of clinician-assessed flare-ups

    Time frame: Through week 28 and week 56

  6. Change from baseline in total volume of HO lesions

    Time frame: At week 28 and week 56

  7. Change from baseline in Tanner puberty scale

    Tanner puberty scale or stages: Staging of sexual development is graded on a 5-point ordinal scale ranging from 1 (prepubertal) to 5 (adultlike) for female breast development, male external genitals, and pubic hair

    Time frame: At week 28 and week 56

  8. Characteristics of menstrual cycles for female participants who reached menarche

    Time frame: Over 28 weeks and 56 weeks

  9. Height-for-age Z-Scores according to the World Health Organization (WHO) Growth Reference Data for Children

    Participants 5-19 years of age Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.

    Time frame: Through week 56

  10. Change from baseline in knee height

    Time frame: At week 28 and week 56

  11. Concentrations of total activin A in serum

    Time frame: Through week 56

  12. Occurence of Anti-Drug Antibody (ADA) to garetosmab

    Time frame: Through week 56

  13. Magnitude of ADA to garetosmab

    Time frame: Through week 56

  14. Change from baseline in hearing function as assessed by audiometry

    Time frame: At week 28 and week 56

  15. Change from baseline in Pediatric Quality of Life inventory (PedsQL) scores

    Age-appropriate PedsQL Generic Core Scales will be used to measure HRQoL in children and adolescents. Response options include 5-point Likert scale (or 3-point Likert scale for the young children self-report) for each item asking about experience within the past week. Global scores are transformed to a 0 to 100 scale with higher scores indicating better quality of life.

    Time frame: At week 28 and week 56

  16. Acceptability or tolerability assessment via exit interview

    Each interview will be conducted by trained external interviewers following a semi-structured interview guide of questions for the participants about their overall experience in the trial.

    Time frame: Up to week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Jul 2030, 41 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2028 → Jul 2030 and completion Dec 2029 → Jul 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 30, 2026
StartEst.
Feb 2, 2027
Primary completionEst.
Jul 8, 2030was Dec 2028
CompletionEst.
Jul 8, 2030was Dec 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 10, 2028→Jul 8, 2030
Oct 8, 2026
Study completion
Dec 21, 2029→Jul 8, 2030
Oct 8, 2026
Eligibility
4 criteria added, 3 removed
What changed in the criteria
  • RemovedCohort 1 > 30 kg
  • RemovedCohort 2 > 30 kg
  • RemovedCohort 3 ≤ 30 kg
  • AddedCohort 1: more than 30 kg (or 66.1 pounds)
  • AddedCohort 2: more than 30 kg (or 66.1 pounds)
  • AddedCohort 3: less than or equal to 30 kg (or 66.1 pounds)
  • AddedParticipants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization
Oct 8, 2026
Primary outcomes
2 time frame changed, 2 removed
What changed in the outcomes
  • RemovedOccurrence of TEAEsTime frame: Baseline to week 56
  • RemovedSeverity of TEAEsTime frame: Baseline to week 56
  • Time frameOccurrence of Treatment-Emergent Adverse Event (TEAEs)Baseline to week 28 → Baseline to week 56
  • Time frameSeverity of TEAEsBaseline to week 28 → Baseline to week 56
Oct 8, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 8, 2026
  • EditedTotal volume of new Heterotopic Ossification (HO) lesionlesionsTime frame: At week 28 and week 56
  • EditedAcceptability andor tolerability assessment via exit interviewTime frame: Up to week 30
  • AddedChange from baseline in total volume of HO lesionsTime frame: At week 28 and week 56
  • AddedChange from baseline in knee heightTime frame: At week 28 and week 56
  • RemovedNumber of patient/caregiver-reported flare-upsTime frame: Through Week 28 and week 56
  • RemovedOccurrence of patient/caregiver-reported flare-upsTime frame: Through week 28 and week 56
What changed on Nov 12, 2026
  • Time frameAcceptability or tolerability assessment via exit interviewUp to week 30 → Up to week 52
across 2 updates, Oct 8, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameAcceptability or tolerability assessment via exit interviewUp to week 30 → Up to week 52
    + 1 other change: verification date
  2. Oct 20, 2026
    Minor edits only
    + 1 other change: arm descriptions
  3. Oct 8, 2026
    Primary completion Dec 10, 2028→Jul 8, 2030
    Study completion Dec 21, 2029→Jul 8, 2030
    Eligibility 4 criteria added, 3 removed
    What changed in the criteria
    • RemovedCohort 1 > 30 kg
    • RemovedCohort 2 > 30 kg
    • RemovedCohort 3 ≤ 30 kg
    • AddedCohort 1: more than 30 kg (or 66.1 pounds)
    • AddedCohort 2: more than 30 kg (or 66.1 pounds)
    • AddedCohort 3: less than or equal to 30 kg (or 66.1 pounds)
    • AddedParticipants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization
    Primary outcomes 2 time frame changed, 2 removed
    What changed in the outcomes
    • RemovedOccurrence of TEAEsTime frame: Baseline to week 56
    • RemovedSeverity of TEAEsTime frame: Baseline to week 56
    • Time frameOccurrence of Treatment-Emergent Adverse Event (TEAEs)Baseline to week 28 → Baseline to week 56
    • Time frameSeverity of TEAEsBaseline to week 28 → Baseline to week 56
    Secondary outcomes 2 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedTotal volume of new Heterotopic Ossification (HO) lesionlesionsTime frame: At week 28 and week 56
    • EditedAcceptability andor tolerability assessment via exit interviewTime frame: Up to week 30
    • AddedChange from baseline in total volume of HO lesionsTime frame: At week 28 and week 56
    • AddedChange from baseline in knee heightTime frame: At week 28 and week 56
    • RemovedNumber of patient/caregiver-reported flare-upsTime frame: Through Week 28 and week 56
    • RemovedOccurrence of patient/caregiver-reported flare-upsTime frame: Through week 28 and week 56
    + 5 other changes: index terms, verification date, description, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07559513
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Feb 2, 2027 (estimated)
Primary completion
Jul 8, 2030 (estimated)
Completion
Jul 8, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion